Targeted pill shows promise in slowing advanced cancers with specific gene flaws
NCT ID NCT04233567
Summary
This study tested an oral drug called infigratinib in adults with advanced or metastatic solid tumors that have specific changes in FGFR genes. The goal was to see if blocking these overactive proteins could stop or slow tumor growth. Participants took the pill daily in repeating cycles for as long as it was effective and they could tolerate it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.